GLYC - GlycoMimetics, Inc.
10.59 0.00 (0.00%)
After hours: 4:34PM EST
| Previous Close | 10.69 |
| Open | 10.64 |
| Bid | 10.05 x 800 |
| Ask | 12.60 x 900 |
| Day's Range | 10.49 - 10.92 |
| 52 Week Range | 8.29 - 26.05 |
| Volume | 135,682 |
| Avg. Volume | 325,253 |
| Market Cap | 456.823M |
| Beta (3Y Monthly) | 3.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.12 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.40 |
- Simply Wall St.•last month
Here’s What We Think About GlycoMimetics, Inc.’s (NASDAQ:GLYC) CEO Pay
Rachel King has been the CEO of GlycoMimetics, Inc. (NASDAQ:GLYC) since 2003. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider Read More...
- Business Wire•last month
GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates
GlycoMimetics, Inc. (GLYC) shared at the 60th American Society of Hematology (ASH) Annual Meeting yesterday two posters with preclinical data presentations: on GMI-1687, the company’s highly potent E-selectin antagonist that is bioavailable via subcutaneous administration, and GMI-1757, the company’s dual-function E-selectin/galectin-3 antagonist. “The new preclinical data presented at ASH underscore GlycoMimetics’ commitment to pioneering advances in the field of glycobiology and to rationally designing innovative drug candidates that address areas of significant unmet medical need,” said John Magnani, Ph.D., Senior Vice President and Chief Scientific Officer.
- Business Wire•2 months ago
GlycoMimetics Presents New AML Data with Uproleselan at 60th ASH Annual Meeting
ROCKVILLE, Md.-- -- Data in relapsed/refractory and newly diagnosed acute myeloid leukemia patients underscore clinical opportunities across multiple outcomes measures and subgroups Selective disruption of bone marrow microenvironment with uproleselan resulting in high remission rates; majority of evaluable patients achieving stringent level of measurable residual disease negativity; promising survival ...
- Business Wire•2 months ago
GlycoMimetics to Host 2018 Investor/Analyst Meeting at 60th ASH Annual Meeting on December 3, 2018
GlycoMimetics, Inc. (GLYC) announced today that it will host and webcast an investor/analyst meeting and update at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, on December 3 at 6 a.m. PT. Daniel J. DeAngelo, MD, PhD, Director of Clinical and Translational Research, Adult Leukemia Program, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Associate Professor of Medicine, Harvard Medical School, who served as lead investigator of the GlycoMimetics’ recently completed Phase 1/2 clinical trial of uproleselan in acute myeloid leukemia patients, will recap and provide perspective on his December 2 oral presentation at the ASH meeting, highlighting the trial’s findings. GlycoMimetics management will review additional posters from the ASH meeting.
- Business Wire•2 months ago
Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors
GlycoMimetics, Inc. (GLYC) today announced that it has appointed Scott Jackson, former Chief Executive Officer of Celator Pharmaceuticals, Inc., to its Board of Directors. Mr. Jackson served as Celator’s CEO and as a member of its Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. Mr. Jackson has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical and YM BioSciences. He holds a B.S. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. Mr. Jackson presently serves on the Board of Directors of MacroGenics, Inc. and the Board of Trustees of the Eastern Pennsylvania Chapter of The Leukemia and Lymphoma Society.
- Motley Fool•2 months ago
3 Top Biotech Stocks to Buy Right Now
Ignoring these promising biotech stocks could be a mistake.
- Business Wire•2 months ago
GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
GlycoMimetics, Inc. (GLYC) announced today dosing of the first patient in the company’s Phase 3 clinical trial of uproleselan (GMI-1271) in relapsed/refractory AML. The company anticipates the initiation of two complementary Phase 2/3 trials from two leading clinical consortia in early 2019.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of GLYC earnings conference call or presentation 2-Nov-18 12:30pm GMT
Q3 2018 GlycoMimetics Inc Earnings Call
- GlobeNewswire•2 months ago
Report: Developing Opportunities within Stryker, Anavex Life Sciences, Engility, Baker Hughes, a GE company, GlycoMimetics, and HCP — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Associated Press•3 months ago
GlycoMimetics: 3Q Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 27 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- Business Wire•3 months ago
GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements
ROCKVILLE, Md.-- -- Continued to select new clinical sites and ready previously-selected sites in the U.S., Europe, Canada and Australia for the company-sponsored Phase 3 pivotal trial in relapsed/refractory AML; study now open for enrollment Received notice of Japanese patent issuance in August for uproleselan composition of matter as well as pharmaceutical formulations, expiring in December 2032 ...
- Business Wire•3 months ago
GlycoMimetics to Present Analyses from Phase 1/2 AML Trial of Uproleselan at 60th ASH Meeting
ROCKVILLE, Md.-- -- New and updated clinical outcomes data and subgroup analyses continue to demonstrate potential benefit of treatment with uproleselan when added to chemotherapy 69 percent of evaluable patients with relapsed/refractory acute myeloid leukemia and 56 percent of evaluable patients with newly diagnosed AML achieved MRD-negative remission in clinical trial Correlation of E-selectin ligand ...
- Business Wire•3 months ago
GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018
GlycoMimetics, Inc. (GLYC) announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2018 financial results on Friday, November 2, 2018, at 8:30 a.m. ET. To access the live audio webcast, or the subsequent archived recording, visit the “Investors - Events & Presentations” section of the GlycoMimetics website at www.glycomimetics.com. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.
- Business Wire•3 months ago
GlycoMimetics to Present at Upcoming Investor Conferences
GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at two upcoming investor conferences, as follows:
- Zacks•3 months ago
Neurocrine Inks Deal with Private Biotech to Make CNS Drugs
Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of GLYC earnings conference call or presentation 10-Aug-18 12:30pm GMT
Q2 2018 GlycoMimetics Inc Earnings Call
- Business Wire•5 months ago
GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271)
GlycoMimetics, Inc. (GLYC), a biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates to treat rare diseases, announced today that the Japan Patent Office (JPO) has issued Patent No. 6366150, for uproleselan (GMI-1271). The newly issued patent covers uproleselan’s composition of matter as well as pharmaceutical formulations, and expires in December 2032. “The JPO’s issuance of a patent for uproleselan extends major market intellectual property coverage for this E-selectin antagonist drug candidate,” stated Rachel King, GlycoMimetics’ Chief Executive Officer.
Motley Fool•5 months agoGlycoMimetics (GLYC) Q2 2018 Earnings Conference Call Transcript
GLYC earnings call for the period ending June 30, 2018.
- InvestorPlace•5 months ago
GlycoMimetics Stock Has Substantial Upside
GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. Its cash position was at high enough levels to cover future operational needs. GlycoMimetics ended the second quarter (Jun. 30, 2018) with $229.4 million in cash.
- ACCESSWIRE•5 months ago
GlycoMimetics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / GlycoMimetics, Inc. (NASDAQ: GLYC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 10, 2018 at 8:30 AM Eastern Time. ...
- Associated Press•5 months ago
GlycoMimetics: 2Q Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 26 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- Business Wire•5 months ago
GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements
ROCKVILLE, Md.-- -- Announced a Cooperative Research and Development Agreement to collaborate with the National Cancer Institute and the Alliance for Clinical Trials in Oncology to fund a planned pivotal Phase 3 trial to evaluate uproleselan in older, newly diagnosed acute myeloid leukemia patients eligible for intensive chemotherapy Continued to select new clinical sites and ready previously-selected ...
- Business Wire•6 months ago
GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018
GlycoMimetics, Inc. (GLYC) announced today that it will report its second quarter 2018 financial results on Thursday August 9, 2018, and will host a conference call and webcast on Friday, August 10, 2018, at 8:30 a.m. ET. To access the live audio webcast, or the subsequent archived recording, visit the “Investors - Events & Presentations” section of the GlycoMimetics website at www.glycomimetics.com. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.
